{"protocolSection":{"identificationModule":{"nctId":"NCT05262023","orgStudyIdInfo":{"id":"DNLI-H-0001"},"secondaryIdInfos":[{"id":"2023-508697-28-00","type":"CTIS"},{"id":"2021-005733-16","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Denali Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)","officialTitle":"A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-02-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-02-01","studyFirstSubmitQcDate":"2022-02-26","studyFirstPostDateStruct":{"date":"2022-03-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-13","lastUpdatePostDateStruct":{"date":"2026-01-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Denali Therapeutics Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Takeda","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period.\n\nPart A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B."},"conditionsModule":{"conditions":["Frontotemporal Dementia"],"keywords":["FTD","FTD-GRN","granulin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":85,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DNL593 (Healthy Participant)","type":"EXPERIMENTAL","interventionNames":["Drug: DNL593"]},{"label":"Placebo (Healthy Participant)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"DNL593 (Participants with FTD)","type":"EXPERIMENTAL","interventionNames":["Drug: DNL593"]},{"label":"Placebo (Participants with FTD)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"DNL593","description":"Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)","armGroupLabels":["DNL593 (Healthy Participant)","DNL593 (Participants with FTD)"]},{"type":"DRUG","name":"Placebo","description":"Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)","armGroupLabels":["Placebo (Healthy Participant)","Placebo (Participants with FTD)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)","timeFrame":"up to 18 months"},{"measure":"Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: systolic and diastolic blood pressure","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: heart rate","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: respiratory rate","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: body temperature","timeFrame":"up to 18 months"},{"measure":"Change from baseline in electrocardiogram (ECG) results including PR, QRS, and QTcF intervals","timeFrame":"up to 18 months"},{"measure":"Incidence of treatment-emergent clinically significant abnormalities in physical/neurological examination findings","timeFrame":"up to 18 months"},{"measure":"Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS; Parts B and C only)","timeFrame":"up to 18 months"}],"secondaryOutcomes":[{"measure":"PK Parameter: Maximum concentration (Cmax) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: Time to reach maximum concentration (tmax) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: Area under the concentration-time curve (AUC) from time zero to time of last measurable concentration (AUClast) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: terminal elimination half-life (t1/2) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: AUC from time zero to infinity (AUC∞) of DNL593 in serum (Part A only)","timeFrame":"up to 84 days"},{"measure":"PK Parameter: Accumulation ratio of DNL593 in serum (Parts B and C only)","timeFrame":"up to 18 months"},{"measure":"PK Parameter: Trough concentration of DNL593 in serum (Ctrough) (Parts B and C only)","timeFrame":"up to 18 months"},{"measure":"PK Parameter: AUC from time 0 to the end of the dosing interval (AUCτ) of DNL593 in serum (Parts B and C only)","timeFrame":"up to 18 months"},{"measure":"Concentration of DNL593 in cerebrospinal fluid (CSF)","timeFrame":"up to 18 months"},{"measure":"DNL593 CSF:serum concentration ratio","timeFrame":"up to 18 months"},{"measure":"Percentage change from baseline in plasma NfL","timeFrame":"up to 18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\nPart A:\n\n* Women of non-childbearing potential (surgically sterilized or post menopausal) or men, aged ≥18 to ≤ 55 years\n* BMI of ≥ 18 to ≤ 32 kg/m²\n* When engaging in sex with a woman of child bearing potential, two forms of birth control are required\n\nPart B:\n\n* Women of non-childbearing potential (surgically sterilized or post menopausal) or men, aged ≥18 to ≤ 80 years. Women who are of childbearing potential but on highly effective, low user dependent contraceptive methods will be allowed.\n* BMI of ≥ 18 to ≤ 32 kg/m²\n* Have a Clinical Dementia Rating® plus National Alzheimer's Coordinating Center frontotemporal lobar degeneration global score ≥ 0.5\n* Have confirmed granulin (GRN) mutation via genetic testing or historical records available for review by investigator\n* When engaging in sex with a woman of child bearing potential, both the male participant and his female partner must use highly effective contraception\n\nPart C:\n\n* All participants who completed Part B of this trial are eligible for an 18-month OLE if the participant has no unresolved clinically significant TEAEs, where continued dosing may represent a risk to participant safety.\n\nKey Exclusion Criteria:\n\n* Have any history of clinically significant neurologic, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders\n* Have a history of malignancy, except fully resected basal cell carcinoma or other malignancies at low risk of recurrence\n* Have a clinically significant history of stroke, cognitive impairment due to causes other than FTD, seizure within 5 years of screening, or head trauma with loss of consciousness within 2 years of screening\n* Have a positive serum pregnancy test or are currently lactating or breastfeeding","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Amy Berger, MD","affiliation":"Denali Therapeutics Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of California San Francisco","city":"San Francisco","state":"California","zip":"94143","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"John Hopkins University","city":"Baltimore","state":"Maryland","zip":"21218","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Antwerp","city":"Antwerp","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}},{"facility":"UZ Leuven","city":"Leuven","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"L2IP - Instituto de Pesquisas Clinicas LTDA","city":"Brasília","country":"Brazil","geoPoint":{"lat":-15.77972,"lon":-47.92972}},{"facility":"Faculdade de Medicina Da Universidade de São Paulo","city":"São Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Hospital Universitario San Ignacio","city":"Bogotá","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Grupo de Neurosicencias de la Universidad de Antioquia","city":"Medellín","country":"Colombia","geoPoint":{"lat":6.245,"lon":-75.57151}},{"facility":"Fakultni nemocnice v Motole","city":"Prague","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"CHU de Nantes","city":"Nantes","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"CHU Rouen","city":"Rouen","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"CHU Toulouse","city":"Toulouse","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"ASST degli Spedali Civili di Brescia","city":"Brescia","country":"Italy","geoPoint":{"lat":45.53558,"lon":10.21472}},{"facility":"Azienda Ospedaliera Universitaria Careggi","city":"Florence","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"IRCCS Istituto Auxologico Italiano","city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Azienda Ospedaliera Cardinale G Panico","city":"Tricase","country":"Italy","geoPoint":{"lat":39.93018,"lon":18.35421}},{"facility":"Erasmus University Medical Center","city":"Rotterdam","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Hospital de Braga","city":"Braga","country":"Portugal","geoPoint":{"lat":41.5514,"lon":-8.42311}},{"facility":"Campus Neurológico Sénior","city":"Torres Vedras","country":"Portugal","geoPoint":{"lat":39.09109,"lon":-9.2586}},{"facility":"Hospital Clinic de Barcelona","city":"Barcelona","state":"Barcelona","zip":"8036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario de Donostia","city":"Donostia / San Sebastian","state":"Guipúzcoa","zip":"20014","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","state":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Istanbul University Istanbul Medical Faculty","city":"Istanbul","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ondokuz Mayis University Hospital","city":"Samsun","country":"Turkey (Türkiye)","geoPoint":{"lat":41.27976,"lon":36.3361}},{"facility":"Simbec Orion","city":"Merthyr Tydfil","state":"Wales","zip":"CF48 4DR","country":"United Kingdom","geoPoint":{"lat":51.74794,"lon":-3.37779}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25","removedCountries":["Serbia"]},"conditionBrowseModule":{"meshes":[{"id":"D057180","term":"Frontotemporal Dementia"}],"ancestors":[{"id":"D057174","term":"Frontotemporal Lobar Degeneration"},{"id":"D003704","term":"Dementia"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D057177","term":"TDP-43 Proteinopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D057165","term":"Proteostasis Deficiencies"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D019965","term":"Neurocognitive Disorders"},{"id":"D001523","term":"Mental Disorders"}]}},"hasResults":false}